Pharmaceuticals company Cipla announced Q1FY27 results Consolidated Financial Highlights: The company reported a Total Income of Rs 7,330.18 crore for Q1FY27, reflecting a marginal YoY increase of 1.58% compared to Rs 7,216.03 crore in Q1FY26 and a QoQ growth of 9.58% from Rs 6,689.36 crore in Q4FY26. Total Revenue from operations stood at Rs 7,119.28 crore in Q1FY27, an increase of 2.33% YoY from Rs 6,957.47 crore in Q1FY26 and a growth of 8.84% QoQ against Rs 6,541.20 crore in Q4FY26. Other Income for the quarter was Rs 210.90 crore, down 18.43% YoY from Rs 258.56 crore in Q1FY26, but up 42.35% QoQ from Rs 148.16 crore in Q4FY26. Profit before tax (and share of profit/loss from associates) reached Rs 1,081.93 crore in Q1FY27, representing a YoY decline of 38.87% compared to Rs 1,769.93 crore in Q1FY26, while showing a QoQ growth of 53.02% from Rs 707.06 crore in Q4FY26. Net profit for the period attributable to owners of the parent was Rs 789.05 crore in Q1FY27, marking a YoY decrease of 39.19% from Rs 1,297.62 crore in Q1FY26, but a QoQ increase of 42.26% compared to Rs 554.64 crore in Q4FY26. Total comprehensive income for Q1FY27 was Rs 979.61 crore, showing a YoY decline of 28.65% from Rs 1,373.02 crore in Q1FY26 and a QoQ increase of 44.42% from Rs 678.30 crore in Q4FY26. Standalone Financial Highlights: Total Income for Q1FY27 was Rs 5,320.43 crore, remaining nearly flat with a 0.06% YoY increase from Rs 5,317.24 crore in Q1FY26, and reflecting a 21.19% QoQ growth from Rs 4,390.20 crore in Q4FY26. Total Revenue from operations stood at Rs 5,077.68 crore in Q1FY27, a marginal YoY increase of 0.62% from Rs 5,046.17 crore in Q1FY26 and a significant QoQ growth of 20.61% from Rs 4,209.98 crore in Q4FY26. Net profit after tax for the quarter was Rs 862.16 crore, a YoY decline of 33.84% compared to Rs 1,303.13 crore in Q1FY26, but a substantial QoQ increase of 124.15% from Rs 384.64 crore in Q4FY26. Total comprehensive income for the period stood at Rs 929.44 crore in Q1FY27, down 28.46% YoY from Rs 1,299.22 crore in Q1FY26, but up 182.28% QoQ from Rs 329.26 crore in Q4FY26. Business Highlights: Amalgamation Update: The Board of Directors approved the Scheme of Amalgamation of Inzpera Healthsciences Limited (a wholly owned subsidiary) with Cipla Limited on March 19, 2026. The scheme is currently awaiting approval from the Hon’ble National Company Law Tribunal (NCLT), Mumbai. NPPA Litigation: The company is currently in litigation regarding demand notices from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging. The total amount under litigation, after removing duplications, aggregates to Rs 2,011 crore (principal of Rs 863 crore and interest of Rs 1,148 crore). The company expects a favorable outcome and has not made a provision for this. Equity Capital: During Q1FY27, the paid-up equity share capital increased to Rs 161.57 crore following the allotment of 54,903 equity shares and 7,782 equity shares under employee stock option and appreciation rights schemes. New Labour Codes: The Group recognized an incremental gratuity and leave liability aggregating Rs 275.91 crore as an exceptional item in FY26 due to the revised definition of "wages" under the 'New Labour Codes'. Change in Revenue Presentation: Effective April 1, 2026, the Group began presenting certain marketing and promotional expenditures as a reduction from Revenue from Operations. For comparison, such expenditures amounted to Rs 115.24 crore in Q1FY26 and Rs 145.13 crore in Q4FY26. Result PDF